Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines.
Identifieur interne : 000096 ( Main/Exploration ); précédent : 000095; suivant : 000097Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines.
Auteurs : Edward W. Thommes [Canada] ; Morgan Kruse [États-Unis] ; Michele Kohli [Canada] ; Rohita Sharma [Canada] ; Stephen G. Noorduyn [Canada]Source :
- Human vaccines & immunotherapeutics [ 2164-554X ] ; 2017.
Descripteurs français
- KwdFr :
- Analyse coût-bénéfice (MeSH), Canada (épidémiologie), Coûts indirects de la maladie (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (économie), Grippe humaine (épidémiologie), Humains (MeSH), Modèles statistiques (MeSH), Vaccination (économie), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie), Vaccins antigrippaux (économie), Vaccins inactivés (administration et posologie), Vaccins inactivés (immunologie), Vaccins inactivés (économie), Victoria (MeSH).
- MESH :
- administration et posologie : Vaccins antigrippaux, Vaccins inactivés.
- immunologie : Vaccins antigrippaux, Vaccins inactivés.
- prévention et contrôle : Grippe humaine.
- économie : Grippe humaine, Vaccination, Vaccins antigrippaux, Vaccins inactivés.
- épidémiologie : Canada, Grippe humaine.
- Analyse coût-bénéfice, Coûts indirects de la maladie, Humains, Modèles statistiques, Victoria.
English descriptors
- KwdEn :
- Canada (epidemiology), Cost of Illness (MeSH), Cost-Benefit Analysis (MeSH), Humans (MeSH), Influenza Vaccines (administration & dosage), Influenza Vaccines (economics), Influenza Vaccines (immunology), Influenza, Human (economics), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Models, Statistical (MeSH), Vaccination (economics), Vaccines, Inactivated (administration & dosage), Vaccines, Inactivated (economics), Vaccines, Inactivated (immunology), Victoria (MeSH).
- MESH :
- chemical , administration & dosage : Influenza Vaccines, Vaccines, Inactivated.
- chemical , economics : Influenza Vaccines, Vaccines, Inactivated.
- economics : Influenza, Human, Vaccination.
- epidemiology : Canada, Influenza, Human.
- chemical , immunology : Influenza Vaccines, Vaccines, Inactivated.
- prevention & control : Influenza, Human.
- Cost of Illness, Cost-Benefit Analysis, Humans, Models, Statistical, Victoria.
Abstract
In the 2015/16 influenza season, the Canadian National Advisory Committee on Immunization (NACI) recommended vaccination with quadrivalent inactivated influenza vaccine (QIV) for infants aged 6-23 months and trivalent inactivated influenza vaccines (TIVs) or QIVs in adults. The objective of this review (GSK study identifier: HO-13-14054) is to examine the epidemiology and disease burden of influenza in Canada and the economic benefits of vaccination. To inform this review, we performed a systematic literature search of relevant Canadian literature and National surveillance data. Influenza B viruses from phylogenetically-distinct lineages (B/Yamagata and B/Victoria) co-circulate in Canada, and are an important cause of influenza complications. Modeling studies, including those postdating the search suggest that switching from TIV to QIV in Canada reduces the burden of influenza and would likely be cost-effective. However, more robust real-world outcomes data is required to inform health policy decision makers on appropriate influenza vaccination strategies for Canada.
DOI: 10.1080/21645515.2016.1251537
PubMed: 27858509
PubMed Central: PMC5404371
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines.</title><author><name sortKey="Thommes, Edward W" sort="Thommes, Edward W" uniqKey="Thommes E" first="Edward W" last="Thommes">Edward W. Thommes</name><affiliation wicri:level="1"><nlm:affiliation>a GSK, Health Economics and Outcomes Research , Mississauga , Ontario , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>a GSK, Health Economics and Outcomes Research , Mississauga , Ontario </wicri:regionArea><wicri:noRegion>Ontario </wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>b Department of Mathematics and Statistics , University of Guelph , Guelph , Ontario , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>b Department of Mathematics and Statistics , University of Guelph , Guelph , Ontario </wicri:regionArea><wicri:noRegion>Ontario </wicri:noRegion></affiliation></author><author><name sortKey="Kruse, Morgan" sort="Kruse, Morgan" uniqKey="Kruse M" first="Morgan" last="Kruse">Morgan Kruse</name><affiliation wicri:level="2"><nlm:affiliation>c Optum, Health Economics and Outcomes Research , San Jose , CA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>c Optum, Health Economics and Outcomes Research , San Jose , CA </wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Kohli, Michele" sort="Kohli, Michele" uniqKey="Kohli M" first="Michele" last="Kohli">Michele Kohli</name><affiliation wicri:level="1"><nlm:affiliation>d Optum, Health Economics and Outcomes Research , Burlington , Ontario , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>d Optum, Health Economics and Outcomes Research , Burlington , Ontario </wicri:regionArea><wicri:noRegion>Ontario </wicri:noRegion></affiliation></author><author><name sortKey="Sharma, Rohita" sort="Sharma, Rohita" uniqKey="Sharma R" first="Rohita" last="Sharma">Rohita Sharma</name><affiliation wicri:level="1"><nlm:affiliation>e GSK, Medical Affairs , Mississauga , Ontario , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>e GSK, Medical Affairs , Mississauga , Ontario </wicri:regionArea><wicri:noRegion>Ontario </wicri:noRegion></affiliation></author><author><name sortKey="Noorduyn, Stephen G" sort="Noorduyn, Stephen G" uniqKey="Noorduyn S" first="Stephen G" last="Noorduyn">Stephen G. Noorduyn</name><affiliation wicri:level="1"><nlm:affiliation>f GSK, Health Economics and Outcomes Research , Mississauga , Ontario , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>f GSK, Health Economics and Outcomes Research , Mississauga , Ontario </wicri:regionArea><wicri:noRegion>Ontario </wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27858509</idno><idno type="pmid">27858509</idno><idno type="doi">10.1080/21645515.2016.1251537</idno><idno type="pmc">PMC5404371</idno><idno type="wicri:Area/Main/Corpus">000125</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000125</idno><idno type="wicri:Area/Main/Curation">000125</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000125</idno><idno type="wicri:Area/Main/Exploration">000125</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines.</title><author><name sortKey="Thommes, Edward W" sort="Thommes, Edward W" uniqKey="Thommes E" first="Edward W" last="Thommes">Edward W. Thommes</name><affiliation wicri:level="1"><nlm:affiliation>a GSK, Health Economics and Outcomes Research , Mississauga , Ontario , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>a GSK, Health Economics and Outcomes Research , Mississauga , Ontario </wicri:regionArea><wicri:noRegion>Ontario </wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>b Department of Mathematics and Statistics , University of Guelph , Guelph , Ontario , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>b Department of Mathematics and Statistics , University of Guelph , Guelph , Ontario </wicri:regionArea><wicri:noRegion>Ontario </wicri:noRegion></affiliation></author><author><name sortKey="Kruse, Morgan" sort="Kruse, Morgan" uniqKey="Kruse M" first="Morgan" last="Kruse">Morgan Kruse</name><affiliation wicri:level="2"><nlm:affiliation>c Optum, Health Economics and Outcomes Research , San Jose , CA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>c Optum, Health Economics and Outcomes Research , San Jose , CA </wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Kohli, Michele" sort="Kohli, Michele" uniqKey="Kohli M" first="Michele" last="Kohli">Michele Kohli</name><affiliation wicri:level="1"><nlm:affiliation>d Optum, Health Economics and Outcomes Research , Burlington , Ontario , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>d Optum, Health Economics and Outcomes Research , Burlington , Ontario </wicri:regionArea><wicri:noRegion>Ontario </wicri:noRegion></affiliation></author><author><name sortKey="Sharma, Rohita" sort="Sharma, Rohita" uniqKey="Sharma R" first="Rohita" last="Sharma">Rohita Sharma</name><affiliation wicri:level="1"><nlm:affiliation>e GSK, Medical Affairs , Mississauga , Ontario , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>e GSK, Medical Affairs , Mississauga , Ontario </wicri:regionArea><wicri:noRegion>Ontario </wicri:noRegion></affiliation></author><author><name sortKey="Noorduyn, Stephen G" sort="Noorduyn, Stephen G" uniqKey="Noorduyn S" first="Stephen G" last="Noorduyn">Stephen G. Noorduyn</name><affiliation wicri:level="1"><nlm:affiliation>f GSK, Health Economics and Outcomes Research , Mississauga , Ontario , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>f GSK, Health Economics and Outcomes Research , Mississauga , Ontario </wicri:regionArea><wicri:noRegion>Ontario </wicri:noRegion></affiliation></author></analytic><series><title level="j">Human vaccines & immunotherapeutics</title><idno type="eISSN">2164-554X</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Canada (epidemiology)</term><term>Cost of Illness (MeSH)</term><term>Cost-Benefit Analysis (MeSH)</term><term>Humans (MeSH)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (economics)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (economics)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Models, Statistical (MeSH)</term><term>Vaccination (economics)</term><term>Vaccines, Inactivated (administration & dosage)</term><term>Vaccines, Inactivated (economics)</term><term>Vaccines, Inactivated (immunology)</term><term>Victoria (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse coût-bénéfice (MeSH)</term><term>Canada (épidémiologie)</term><term>Coûts indirects de la maladie (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (économie)</term><term>Grippe humaine (épidémiologie)</term><term>Humains (MeSH)</term><term>Modèles statistiques (MeSH)</term><term>Vaccination (économie)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (immunologie)</term><term>Vaccins antigrippaux (économie)</term><term>Vaccins inactivés (administration et posologie)</term><term>Vaccins inactivés (immunologie)</term><term>Vaccins inactivés (économie)</term><term>Victoria (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Influenza, Human</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Canada</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Grippe humaine</term><term>Vaccination</term><term>Vaccins antigrippaux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Canada</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cost of Illness</term><term>Cost-Benefit Analysis</term><term>Humans</term><term>Models, Statistical</term><term>Victoria</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Coûts indirects de la maladie</term><term>Humains</term><term>Modèles statistiques</term><term>Victoria</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the 2015/16 influenza season, the Canadian National Advisory Committee on Immunization (NACI) recommended vaccination with quadrivalent inactivated influenza vaccine (QIV) for infants aged 6-23 months and trivalent inactivated influenza vaccines (TIVs) or QIVs in adults. The objective of this review (GSK study identifier: HO-13-14054) is to examine the epidemiology and disease burden of influenza in Canada and the economic benefits of vaccination. To inform this review, we performed a systematic literature search of relevant Canadian literature and National surveillance data. Influenza B viruses from phylogenetically-distinct lineages (B/Yamagata and B/Victoria) co-circulate in Canada, and are an important cause of influenza complications. Modeling studies, including those postdating the search suggest that switching from TIV to QIV in Canada reduces the burden of influenza and would likely be cost-effective. However, more robust real-world outcomes data is required to inform health policy decision makers on appropriate influenza vaccination strategies for Canada.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27858509</PMID><DateCompleted><Year>2017</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Month>04</Month><Day>03</Day></PubDate></JournalIssue><Title>Human vaccines & immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines.</ArticleTitle><Pagination><MedlinePgn>867-876</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2016.1251537</ELocationID><Abstract><AbstractText>In the 2015/16 influenza season, the Canadian National Advisory Committee on Immunization (NACI) recommended vaccination with quadrivalent inactivated influenza vaccine (QIV) for infants aged 6-23 months and trivalent inactivated influenza vaccines (TIVs) or QIVs in adults. The objective of this review (GSK study identifier: HO-13-14054) is to examine the epidemiology and disease burden of influenza in Canada and the economic benefits of vaccination. To inform this review, we performed a systematic literature search of relevant Canadian literature and National surveillance data. Influenza B viruses from phylogenetically-distinct lineages (B/Yamagata and B/Victoria) co-circulate in Canada, and are an important cause of influenza complications. Modeling studies, including those postdating the search suggest that switching from TIV to QIV in Canada reduces the burden of influenza and would likely be cost-effective. However, more robust real-world outcomes data is required to inform health policy decision makers on appropriate influenza vaccination strategies for Canada.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thommes</LastName><ForeName>Edward W</ForeName><Initials>EW</Initials><AffiliationInfo><Affiliation>a GSK, Health Economics and Outcomes Research , Mississauga , Ontario , Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b Department of Mathematics and Statistics , University of Guelph , Guelph , Ontario , Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kruse</LastName><ForeName>Morgan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>c Optum, Health Economics and Outcomes Research , San Jose , CA , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohli</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>d Optum, Health Economics and Outcomes Research , Burlington , Ontario , Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Rohita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>e GSK, Medical Affairs , Mississauga , Ontario , Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noorduyn</LastName><ForeName>Stephen G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>f GSK, Health Economics and Outcomes Research , Mississauga , Ontario , Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="Y">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014739" MajorTopicYN="N">Victoria</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">burden</Keyword><Keyword MajorTopicYN="Y">costs</Keyword><Keyword MajorTopicYN="Y">epidemiology</Keyword><Keyword MajorTopicYN="Y">hospitalization</Keyword><Keyword MajorTopicYN="Y">influenza</Keyword><Keyword MajorTopicYN="Y">influenza vaccine</Keyword><Keyword MajorTopicYN="Y">lineage-mismatch</Keyword><Keyword MajorTopicYN="Y">quadrivalent</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27858509</ArticleId><ArticleId IdType="doi">10.1080/21645515.2016.1251537</ArticleId><ArticleId IdType="pmc">PMC5404371</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Infect Control Hosp Epidemiol. 2011 May;32(5):435-43</Citation><ArticleIdList><ArticleId IdType="pubmed">21515973</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinicoecon Outcomes Res. 2012;4:287-98</Citation><ArticleIdList><ArticleId IdType="pubmed">23055756</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2016 Jul 29;34(35):4092-102</Citation><ArticleIdList><ArticleId IdType="pubmed">27381642</ArticleId></ArticleIdList></Reference><Reference><Citation>Acad Emerg Med. 2005 Apr;12(4):338-44</Citation><ArticleIdList><ArticleId IdType="pubmed">15805325</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2013 Jul;144(1):39-47</Citation><ArticleIdList><ArticleId IdType="pubmed">23392627</ArticleId></ArticleIdList></Reference><Reference><Citation>CMAJ. 2010 Mar 9;182(4):349-55</Citation><ArticleIdList><ArticleId IdType="pubmed">20159893</ArticleId></ArticleIdList></Reference><Reference><Citation>Acad Emerg Med. 2013 Apr;20(4):388-97</Citation><ArticleIdList><ArticleId IdType="pubmed">23701347</ArticleId></ArticleIdList></Reference><Reference><Citation>CMAJ. 2010 Dec 14;182(18):1981-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21059773</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Commun Dis Rep. 2001 Jan 1;27(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11195964</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Commun Dis Rep. 2008 Mar;34(3):1-25</Citation><ArticleIdList><ArticleId IdType="pubmed">18404807</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2007 Dec 15;45(12):1568-75</Citation><ArticleIdList><ArticleId IdType="pubmed">18190317</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 Dec 26;369(26):2481-91</Citation><ArticleIdList><ArticleId IdType="pubmed">24328444</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2004 Sep 15;292(11):1333-40</Citation><ArticleIdList><ArticleId IdType="pubmed">15367555</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Curr. 2009 Dec 17;1:RRN1137</Citation><ArticleIdList><ArticleId IdType="pubmed">20043032</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2013 Jul 18;31(33):3370-88</Citation><ArticleIdList><ArticleId IdType="pubmed">23707697</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Commun Dis Rep. 2004 Jun 15;30:1-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15239483</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2013 Nov;7(6):1055-61</Citation><ArticleIdList><ArticleId IdType="pubmed">23145997</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2009 Nov 4;302(17 ):1872-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19822627</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Commun Dis Rep. 2003 Mar 15;29(6):45-59</Citation><ArticleIdList><ArticleId IdType="pubmed">12666540</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Public Health. 2012 Jul;40(5):412-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22798286</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Commun Dis Rep. 2002 Feb 1;28(3):17-28</Citation><ArticleIdList><ArticleId IdType="pubmed">11852481</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2015 Feb 05;20(5):21024</Citation><ArticleIdList><ArticleId IdType="pubmed">25677052</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 2010 Jul;33(7):1491-3</Citation><ArticleIdList><ArticleId IdType="pubmed">20587722</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Public Health. 2009 Sep-Oct;100(5):340-3</Citation><ArticleIdList><ArticleId IdType="pubmed">19994733</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2010 Apr 06;7(4):e1000256</Citation><ArticleIdList><ArticleId IdType="pubmed">20386727</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Public Health. 2013 Feb;103(2):e39-44</Citation><ArticleIdList><ArticleId IdType="pubmed">23237152</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011;6(11):e27420</Citation><ArticleIdList><ArticleId IdType="pubmed">22110645</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Microbiol Infect Dis. 2010 Jul;29(7):835-43</Citation><ArticleIdList><ArticleId IdType="pubmed">20428910</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Infect Control. 2013 Nov;41(11):1032-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24176768</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 2002 Apr;50(4):608-16</Citation><ArticleIdList><ArticleId IdType="pubmed">11982659</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2013 Nov;7(6):1013-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24034594</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2015 Oct 27;15:465</Citation><ArticleIdList><ArticleId IdType="pubmed">26503131</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Sep 7;28 Suppl 4:D45-53</Citation><ArticleIdList><ArticleId IdType="pubmed">20713260</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2011 Apr 12;11:90</Citation><ArticleIdList><ArticleId IdType="pubmed">21486453</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Kidney Dis. 2010 May;55(5):848-55</Citation><ArticleIdList><ArticleId IdType="pubmed">20303633</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Nephrol. 2013 Jun 13;14:123</Citation><ArticleIdList><ArticleId IdType="pubmed">23763900</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Anti Infect Ther. 2013 Jun;11(6):555-63</Citation><ArticleIdList><ArticleId IdType="pubmed">23750727</ArticleId></ArticleIdList></Reference><Reference><Citation>CMAJ. 2009 Aug 4;181(3-4):159-63</Citation><ArticleIdList><ArticleId IdType="pubmed">19620268</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Esp Quimioter. 2015 Feb;28(1):39-46</Citation><ArticleIdList><ArticleId IdType="pubmed">25690144</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Commun Dis Rep. 2006 Apr 1;32(7):77-86</Citation><ArticleIdList><ArticleId IdType="pubmed">16649286</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2006 May 8;24(19):4222-32</Citation><ArticleIdList><ArticleId IdType="pubmed">16423432</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Commun Dis Rep. 2007 Feb 1;33(3):21-41</Citation><ArticleIdList><ArticleId IdType="pubmed">17323533</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin Immunother. 2016 May 3;12(5):1257-64</Citation><ArticleIdList><ArticleId IdType="pubmed">26890128</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Crit Care Med. 2010 Sep;11(5):603-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20308929</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2012 Sep;130(3):397-406</Citation><ArticleIdList><ArticleId IdType="pubmed">22931901</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2006 Sep;118(3):e610-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16950953</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2010 Sep 15;202(6):881-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20677944</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2012 May;6(3):e54-62</Citation><ArticleIdList><ArticleId IdType="pubmed">22385647</ArticleId></ArticleIdList></Reference><Reference><Citation>Wkly Epidemiol Rec. 2009 Nov 20;84(47):485-91</Citation><ArticleIdList><ArticleId IdType="pubmed">19928301</ArticleId></ArticleIdList></Reference><Reference><Citation>CMAJ. 2010 Jan 12;182(1):39-44</Citation><ArticleIdList><ArticleId IdType="pubmed">19926677</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2008 Jan;2(1):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19453488</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2001 Oct 27;358(9291):1410-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11705487</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 Jul 29;10(7):e0133606</Citation><ArticleIdList><ArticleId IdType="pubmed">26222538</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2003 Jan 8;289(2):179-86</Citation><ArticleIdList><ArticleId IdType="pubmed">12517228</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2013 Sep;7(5):799-808</Citation><ArticleIdList><ArticleId IdType="pubmed">23122189</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2014 Dec 1;59(11):1519-24</Citation><ArticleIdList><ArticleId IdType="pubmed">25139969</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin Immunother. 2012 Jan;8(1):81-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22252006</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Infect Dis J. 2011 Aug;30(8):633-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21289529</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Infect Dis J. 2006 Sep;25(9):795-800</Citation><ArticleIdList><ArticleId IdType="pubmed">16940836</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Public Health. 2012 Mar-Apr;103(2):90-3</Citation><ArticleIdList><ArticleId IdType="pubmed">22530528</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2002 Mar 15;34(6):790-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11830797</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Mar 2;30(11):1993-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22226861</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="Canada"><noRegion><name sortKey="Thommes, Edward W" sort="Thommes, Edward W" uniqKey="Thommes E" first="Edward W" last="Thommes">Edward W. Thommes</name></noRegion><name sortKey="Kohli, Michele" sort="Kohli, Michele" uniqKey="Kohli M" first="Michele" last="Kohli">Michele Kohli</name><name sortKey="Noorduyn, Stephen G" sort="Noorduyn, Stephen G" uniqKey="Noorduyn S" first="Stephen G" last="Noorduyn">Stephen G. Noorduyn</name><name sortKey="Sharma, Rohita" sort="Sharma, Rohita" uniqKey="Sharma R" first="Rohita" last="Sharma">Rohita Sharma</name><name sortKey="Thommes, Edward W" sort="Thommes, Edward W" uniqKey="Thommes E" first="Edward W" last="Thommes">Edward W. Thommes</name></country><country name="États-Unis"><region name="Californie"><name sortKey="Kruse, Morgan" sort="Kruse, Morgan" uniqKey="Kruse M" first="Morgan" last="Kruse">Morgan Kruse</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeCanadaV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000096 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000096 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeCanadaV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27858509
|texte= Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27858509" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV4
| This area was generated with Dilib version V0.6.35. |  |